Markets:

Overview

News

Currencies

International

Treasuries

Spero Therapeutics, Inc. - Common Stock (NQ:SPRO)

2.460 +0.030 (+1.23%)

Streaming Delayed Price Updated: 2:52 PM EST, Nov 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Spero Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 30, 2024

Via Benzinga

Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗

October 30, 2024

Via Benzinga

SPRO Stock Earnings: Spero Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 05, 2024

SPRO stock results show that Spero Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

3 Micro-Cap Moonshots for Fearless Investors ↗

July 08, 2024

Investors should know the risks of micro-cap stocks before looking into these three high-potential companies with low prices.

Via InvestorPlace

Recap: Spero Therapeutics Q4 Earnings ↗

March 13, 2024

Via Benzinga

Earnings Outlook For Spero Therapeutics ↗

March 12, 2024

Via Benzinga

Recap: Spero Therapeutics Q3 Earnings ↗

November 13, 2023

Via Benzinga

Earnings Outlook For Spero Therapeutics ↗

November 10, 2023

Via Benzinga

SPRO Stock Earnings: Spero Therapeutics Misses EPS, Misses Revenue for Q1 2024 ↗

May 15, 2024

SPRO stock results show that Spero Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

March 14, 2024

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.

Via Benzinga

Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗

March 14, 2024

Shares of Robinhood Markets, Inc. (NASDAQ: HOOD) rose sharply in today’s pre-market trading after the company reported February trading metrics.

Via Benzinga

4 Analysts Have This to Say About Spero Therapeutics ↗

September 05, 2023

Via Benzinga

Spero Therapeutics's Earnings: A Preview ↗

August 09, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

March 14, 2024

It's time to start the day with a breakdown of all the biggest pre-market stock movers worth watching on Thursday morning!

Via InvestorPlace

Earnings Scheduled For March 13, 2024 ↗

March 13, 2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.

Via Benzinga

Recap: Spero Therapeutics Q1 Earnings ↗

May 11, 2023

Via Benzinga

Spero Therapeutics's Earnings Outlook ↗

May 10, 2023

Via Benzinga

Spero Therapeutics's Earnings: A Preview ↗

March 29, 2023

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

December 04, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 14, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 13, 2023

Via Benzinga

SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

November 02, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

Earnings Outlook For Spero Therapeutics ↗

March 10, 2023

Via Benzinga

Earnings Scheduled For November 13, 2023 ↗

November 13, 2023

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.

Via Benzinga

Overview Of Value Stocks In The Healthcare Sector ↗

September 18, 2023

Via Benzinga

HC Wainwright & Co. Maintains Buy Rating for Spero Therapeutics: Here's What You Need To Know ↗

August 14, 2023

Via Benzinga

Earnings Scheduled For May 11, 2023 ↗

May 11, 2023

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its...

Via Benzinga

Earnings Scheduled For August 10, 2023 ↗

August 10, 2023

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

March 31, 2023

It's time for another dive into the biggest pre-market stock movers with all the hot topics traders need to know about on Friday!

Via InvestorPlace

Earnings Scheduled For March 30, 2023 ↗

March 30, 2023

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Spero Therapeutics, Inc. - Common Stock (NQ:SPRO)

All News about Spero Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today